331 related articles for article (PubMed ID: 33733345)
1. Rivaroxaban for the treatment of cerebral venous thrombosis: a single-center experience.
Bajko Z; Maier S; Motataianu A; Filep RC; Stoian A; Andone S; Balasa R
Acta Neurol Belg; 2022 Feb; 122(1):105-111. PubMed ID: 33733345
[TBL] [Abstract][Full Text] [Related]
2. Is it safe to treat cerebral venous thrombosis with oral rivaroxaban without heparin? A preliminary study from 20 patients.
Shankar Iyer R; Tcr R; Akhtar S; Muthukalathi K; Kumar P; Muthukumar K
Clin Neurol Neurosurg; 2018 Dec; 175():108-111. PubMed ID: 30396036
[TBL] [Abstract][Full Text] [Related]
3. Direct Oral Anticoagulants for the Treatment of Cerebral Venous Thrombosis.
Lurkin A; Derex L; Fambrini A; Bertoletti L; Epinat M; Mismetti P; Dargaud Y
Cerebrovasc Dis; 2019; 48(1-2):32-37. PubMed ID: 31480062
[TBL] [Abstract][Full Text] [Related]
4. Rivaroxaban for the treatment of cerebral venous thrombosis.
Esmaeili S; Abolmaali M; Aarabi S; Motamed MR; Chaibakhsh S; Joghataei MT; Mojtahed M; Mirzaasgari Z
BMC Neurol; 2021 Feb; 21(1):73. PubMed ID: 33588777
[TBL] [Abstract][Full Text] [Related]
5. Comparing the efficacy and safety of direct oral anticoagulants with vitamin K antagonist in cerebral venous thrombosis.
Lee GKH; Chen VH; Tan CH; Leow AST; Kong WY; Sia CH; Chew NWS; Tu TM; Chan BPL; Yeo LLL; Sharma VK; Tan BYQ
J Thromb Thrombolysis; 2020 Oct; 50(3):724-731. PubMed ID: 32279216
[TBL] [Abstract][Full Text] [Related]
6. Apixaban for the treatment of cerebral venous thrombosis: A case series.
Rao SK; Ibrahim M; Hanni CM; Suchdev K; Parker D; Rajamani K; Mohamed W
J Neurol Sci; 2017 Oct; 381():318-320. PubMed ID: 28991706
[TBL] [Abstract][Full Text] [Related]
7. Preliminary findings regarding the use of direct oral anticoagulants in cerebral venous thrombosis.
Hsu A; Mistry H; Lala N; Reagan JL
Clin Neurol Neurosurg; 2020 Nov; 198():106204. PubMed ID: 32937276
[TBL] [Abstract][Full Text] [Related]
8. Non-Vitamin K Antagonist Oral Anticoagulants for the Treatment of Cerebral Venous Sinus Thrombosis: a Retrospective, Matched Cohort Analysis.
Giles JA; Balasetti VKS; Zazulia AR
Neurocrit Care; 2021 Dec; 35(3):783-788. PubMed ID: 34046861
[TBL] [Abstract][Full Text] [Related]
9. Use of direct oral anticoagulants in cerebral venous thrombosis: a systematic review.
Sheng S; Nalleballe K; Pothineni NV; Sharma R; Brown A; Elkhider H; Ranabothu S; Kapoor N; Patrice KA; Onteddu S
Blood Coagul Fibrinolysis; 2020 Dec; 31(8):501-505. PubMed ID: 32941197
[TBL] [Abstract][Full Text] [Related]
10. A Single-Center Retrospective Evaluation of the Use of Oral Factor Xa Inhibitors in Patients With Cerebral Venous Thrombosis.
Powell M; Tremolet de Villers K; Schwarz K; Case D; Trujillo T
Ann Pharmacother; 2021 Mar; 55(3):286-293. PubMed ID: 32844675
[TBL] [Abstract][Full Text] [Related]
11. Endovascular and Medical Management of Cerebral Venous Thrombosis: A Systematic Review and Network Meta-Analysis.
Naik A; Smith E; Dharnipragada R; Catapano JS; Cramer SW; Johnson R; Khanam R; Hassaneen W; Lawton MT; Arnold PM
World Neurosurg; 2022 Sep; 165():e197-e205. PubMed ID: 35688371
[TBL] [Abstract][Full Text] [Related]
12. Novel factor xa inhibitor for the treatment of cerebral venous and sinus thrombosis: first experience in 7 patients.
Geisbüsch C; Richter D; Herweh C; Ringleb PA; Nagel S
Stroke; 2014 Aug; 45(8):2469-71. PubMed ID: 25070963
[TBL] [Abstract][Full Text] [Related]
13. Study of Rivaroxaban for Cerebral Venous Thrombosis: A Randomized Controlled Feasibility Trial Comparing Anticoagulation With Rivaroxaban to Standard-of-Care in Symptomatic Cerebral Venous Thrombosis.
Field TS; Dizonno V; Almekhlafi MA; Bala F; Alhabli I; Wong H; Norena M; Villaluna MK; King-Azote P; Ratnaweera N; Mancini S; Van Gaal SC; Wilson LK; Graham BR; Sposato LA; Blacquiere D; Dewar BM; Boulos MI; Buck BH; Odier C; Perera KS; Pikula A; Tkach A; Medvedev G; Canfield C; Mortenson WB; Nadeau JO; Alshimemeri S; Benavente OR; Demchuk AM; Dowlatshahi D; Lanthier S; Lee AYY; Mandzia J; Suryanarayan D; Weitz JI; Hill MD;
Stroke; 2023 Nov; 54(11):2724-2736. PubMed ID: 37675613
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of long-term anticoagulant treatment for the secondary prophylaxis of splanchnic venous thrombosis.
Serrao A; Merli M; Lucani B; Aprile F; Fiori L; Gioia S; Breccia M; Riggio O; Chistolini A
Eur J Clin Invest; 2021 Jan; 51(1):e13356. PubMed ID: 33180323
[TBL] [Abstract][Full Text] [Related]
15. Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study.
Ageno W; Mantovani LG; Haas S; Kreutz R; Monje D; Schneider J; van Eickels M; Gebel M; Zell E; Turpie AG
Lancet Haematol; 2016 Jan; 3(1):e12-21. PubMed ID: 26765643
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of Direct Oral Anticoagulants in cerebral venous thrombosis: A meta-analysis.
Nepal G; Kharel S; Bhagat R; Ka Shing Y; Ariel Coghlan M; Poudyal P; Ojha R; Sunder Shrestha G
Acta Neurol Scand; 2022 Jan; 145(1):10-23. PubMed ID: 34287841
[TBL] [Abstract][Full Text] [Related]
17. Safety and Efficacy of Dabigatran Etexilate vs Dose-Adjusted Warfarin in Patients With Cerebral Venous Thrombosis: A Randomized Clinical Trial.
Ferro JM; Coutinho JM; Dentali F; Kobayashi A; Alasheev A; Canhão P; Karpov D; Nagel S; Posthuma L; Roriz JM; Caria J; Frässdorf M; Huisman H; Reilly P; Diener HC;
JAMA Neurol; 2019 Dec; 76(12):1457-1465. PubMed ID: 31479105
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Direct Oral Anticoagulants in Cerebral Venous Thrombosis: Meta-Analysis of Randomized Clinical Trials.
Chen X; Guo L; Lin M
Clin Appl Thromb Hemost; 2024; 30():10760296241256360. PubMed ID: 38772568
[TBL] [Abstract][Full Text] [Related]
19. Direct Oral Anticoagulants Versus Warfarin in the Treatment of Cerebral Venous Thrombosis (ACTION-CVT): A Multicenter International Study.
Yaghi S; Shu L; Bakradze E; Salehi Omran S; Giles JA; Amar JY; Henninger N; Elnazeir M; Liberman AL; Moncrieffe K; Lu J; Sharma R; Cheng Y; Zubair AS; Simpkins AN; Li GT; Kung JC; Perez D; Heldner M; Scutelnic A; Seiffge D; Siepen B; Rothstein A; Khazaal O; Do D; Kasab SA; Rahman LA; Mistry EA; Kerrigan D; Lafever H; Nguyen TN; Klein P; Aparicio H; Frontera J; Kuohn L; Agarwal S; Stretz C; Kala N; El Jamal S; Chang A; Cutting S; Xiao H; de Havenon A; Muddasani V; Wu T; Wilson D; Nouh A; Asad SD; Qureshi A; Moore J; Khatri P; Aziz Y; Casteigne B; Khan M; Cheng Y; Mac Grory B; Weiss M; Ryan D; Vedovati MC; Paciaroni M; Siegler JE; Kamen S; Yu S; Leon Guerrero CR; Atallah E; De Marchis GM; Brehm A; Dittrich T; Psychogios M; Alvarado-Dyer R; Kass-Hout T; Prabhakaran S; Honda T; Liebeskind DS; Furie K
Stroke; 2022 Mar; 53(3):728-738. PubMed ID: 35143325
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data.
Kushnir M; Choi Y; Eisenberg R; Rao D; Tolu S; Gao J; Mowrey W; Billett HH
Lancet Haematol; 2019 Jul; 6(7):e359-e365. PubMed ID: 31133411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
